SANDOZ ALMOTRIPTAN DIN 02405334
Status: Marketed
Holder: SANDOZ CANADA INCORPORATED
Molecule: ALMOTRIPTAN (ALMOTRIPTAN MALATE)
Available to quote
Health Canada record
| Active ingredient(s) | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 12.5 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | N02CC05 ALMOTRIPTAN |
| Original market date | 22-Jul-2013 |
| Current status date | 22-Jul-2013 |
| Source | Health Canada DPD |
Establishment licence of the holder
Sandoz Canada Incorporated — licence 101370, currently licensed, last inspection rating C (2025-02-25).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing ALMOTRIPTAN (ALMOTRIPTAN MALATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02570289 | AG-ALMOTRIPTAN | ANGITA PHARMA INC. | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 6.25 MG | Approved |
| 02570297 | AG-ALMOTRIPTAN | ANGITA PHARMA INC. | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 12.5 MG | Approved |
| 02466821 | ALMOTRIPTAN | SANIS HEALTH INC | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 12.5 MG | Marketed |
| 02424029 | ALMOTRIPTAN | PRO DOC LIMITEE | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 12.5 MG | Marketed |
| 02556030 | JAMP ALMOTRIPTAN | JAMP PHARMA CORPORATION | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 12.5 MG | Approved |
| 02556022 | JAMP ALMOTRIPTAN | JAMP PHARMA CORPORATION | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 6.25 MG | Approved |
| 02398435 | MYLAN-ALMOTRIPTAN | MYLAN PHARMACEUTICALS ULC | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 6.25 MG | Marketed |
| 02398443 | MYLAN-ALMOTRIPTAN | MYLAN PHARMACEUTICALS ULC | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 12.5 MG | Marketed |
| 02434849 | TEVA-ALMOTRIPTAN | TEVA CANADA LIMITED | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 12.5 MG | Marketed |
| 02405806 | APO-ALMOTRIPTAN | APOTEX INC | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 12.5 MG | Dormant |
| 02405792 | APO-ALMOTRIPTAN | APOTEX INC | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 6.25 MG | Dormant |
| 02248129 | AXERT 12.5MG | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 12.5 MG | Cancelled Post Market |
| 02248128 | AXERT 6.25MG | MCNEIL CONSUMER HEALTHCARE DIVISION OF JOHNSON & JOHNSON INC | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 6.25 MG | Cancelled Post Market |
| 02441411 | PMS-ALMOTRIPTAN | PHARMASCIENCE INC | Tablet | ALMOTRIPTAN (ALMOTRIPTAN MALATE) 12.5 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 14569 | 2013-07-22 | Abbreviated New Drug Submission (ANDS) |